Latest Kaiser Health News Stories
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Two companies that faced criticism for high-priced drugs, Marathon and Mallinckrodt, have dropped out of the PhRMA trade association.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Kaiser Health News gives readers a chance to respond, react and comment on our stories.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
The drugs, approved by the FDA for children earlier this month, can run $100,000 for a course of treatment.
Amplifying the “patient voice,” those with the rarest afflictions are trained to become powerful advocates for new drugs and legislation that would help the industry.
Unlike heroin, fentanyl routinely shuts down breathing in seconds, and it’s becoming more common.
The vaccine protects kids against infection and several types of cancer but many parents have been reluctant to use it for their children.
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
A cholesterol-lowering drug called Repatha cuts the risk of heart attacks, strokes and heart-related death by 20 percent, according to a new study.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
The numbers show that President Trump’s choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
Dentistry is at a crossroads and many in the field are reassessing their narcotics prescribing habits.